Artwork

コンテンツは Proactive Investors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Proactive Investors またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!

Lumos Diagnostics extends BDI agreement to address clinical needs

5:14
 
シェア
 

Manage episode 436563285 series 2891889
コンテンツは Proactive Investors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Proactive Investors またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Lumos Diagnostics Ltd (ASX:LDX, OTC:LDXHF) chief technology officer Sacha Dopheide joins Proactive’s Tylah Tully to discuss an extended agreement with Burnet Diagnostics Initiative (BDI) to further develop and manufacture a liver function test based on Alanine Transaminase (ALT) levels. The BDI agreement includes the production of ALT lateral flow tests, customised Lumos readers and a mobile application for use in an upcoming US clinical trial. The partnership, which began with a feasibility project in July 2023, aims to address critical clinical needs through rapid point-of-care testing. The new phase of the collaboration is set to begin in August 2024 and will focus on the production of a point-of-care ALT testing system, specifically designed to monitor liver function in high-risk patients. The ALT test is expected to provide rapid results, enabling quicker detection of acute liver toxicity, potentially caused by drug reactions. Lumos will offer development, regulatory and manufacturing services over the next 9-12 months, with projected revenues between US$700,000 and US$1 million. If successful, Lumos may continue to support BDI in further development stages, including additional trials and regulatory submissions. The partnership underlines Lumos’ commitment to advancing point-of-care diagnostics and improving patient outcomes. Partnerships and agreements form a large part of the company’s revenue stream helping it leverage its other client offerings. #Proactiveinvestors #LumosDiagnostics #ASX #HealthcareInnovation, #FDAApproval, #PointOfCare, #MedicalDiagnostics, #WomensHealth, #Hologic, #FebriDx, #ViraDx, #FluSeason, #GlobalHealthcare, #MedicalDevices, #HealthcareSolutions, #RevenueGrowth, #StrategicPartnerships, #Diagnostics, #Biotech, #HealthcareTechnology, #FinancialResults, #MedTech #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

608 つのエピソード

Artwork
iconシェア
 
Manage episode 436563285 series 2891889
コンテンツは Proactive Investors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Proactive Investors またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Lumos Diagnostics Ltd (ASX:LDX, OTC:LDXHF) chief technology officer Sacha Dopheide joins Proactive’s Tylah Tully to discuss an extended agreement with Burnet Diagnostics Initiative (BDI) to further develop and manufacture a liver function test based on Alanine Transaminase (ALT) levels. The BDI agreement includes the production of ALT lateral flow tests, customised Lumos readers and a mobile application for use in an upcoming US clinical trial. The partnership, which began with a feasibility project in July 2023, aims to address critical clinical needs through rapid point-of-care testing. The new phase of the collaboration is set to begin in August 2024 and will focus on the production of a point-of-care ALT testing system, specifically designed to monitor liver function in high-risk patients. The ALT test is expected to provide rapid results, enabling quicker detection of acute liver toxicity, potentially caused by drug reactions. Lumos will offer development, regulatory and manufacturing services over the next 9-12 months, with projected revenues between US$700,000 and US$1 million. If successful, Lumos may continue to support BDI in further development stages, including additional trials and regulatory submissions. The partnership underlines Lumos’ commitment to advancing point-of-care diagnostics and improving patient outcomes. Partnerships and agreements form a large part of the company’s revenue stream helping it leverage its other client offerings. #Proactiveinvestors #LumosDiagnostics #ASX #HealthcareInnovation, #FDAApproval, #PointOfCare, #MedicalDiagnostics, #WomensHealth, #Hologic, #FebriDx, #ViraDx, #FluSeason, #GlobalHealthcare, #MedicalDevices, #HealthcareSolutions, #RevenueGrowth, #StrategicPartnerships, #Diagnostics, #Biotech, #HealthcareTechnology, #FinancialResults, #MedTech #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

608 つのエピソード

Toate episoadele

×
 
Loading …

プレーヤーFMへようこそ!

Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。

 

クイックリファレンスガイド